Vyndaqel patent expiry?

What happens when the Vyndaqel patent expires?

Vyndaqel, also known as tafamidis, is a medication used to treat transthyretin (TTR) amyloidosis [1]. The patent for Vyndaqel is set to expire in 2028, according to DrugPatentWatch.com [2].

Once the patent expires, other companies will be able to produce and sell their own versions of the medication, known as generics or biosimilars. This could lead to increased competition in the market, which may result in lower prices for the drug.

Will generic versions of Vyndaqel be approved?

To be approved as a generic or biosimilar version of Vyndaqel, a new medication must demonstrate bioequivalence to the original drug. This involves showing that the new medication has the same efficacy and safety profile as the original drug. The FDA will be responsible for reviewing and approving any new generic or biosimilar versions of Vyndaqel [3].

How will Vyndaqel's patent expiry affect patients?

The expiration of Vyndaqel's patent could lead to increased accessibility and affordability of the medication for patients with TTR amyloidosis. However, it may take some time for generics or biosimilars to become available, and patients may continue to rely on the original medication during this transition period.

Timeline of Vyndaqel's patent expiry

Vyndaqel's patent is set to expire in 2028, according to DrugPatentWatch.com [2]. This means that pharmaceutical companies will be able to start applying for approval to manufacture and sell generic or biosimilar versions of the medication as early as 2027.

Sources

[1] FDA - Transthyretin (TTR) Amyloidosis [4]
[2] DrugPatentWatch.com - Vyndaqel (tafamidis) [5]
[3] FDA - Biosimilars [6]